Cryoport, Inc. (NASDAQ:CYRX) Receives $61.33 Consensus Target Price from Brokerages

Cryoport, Inc. (NASDAQ:CYRXGet Rating) has received an average recommendation of “Buy” from the seven research firms that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $61.33.

Separately, Needham & Company LLC increased their price objective on Cryoport from $41.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, July 12th.

Insider Buying and Selling at Cryoport

In other news, Director Robert J. Hariri sold 2,000 shares of the firm’s stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $43.29, for a total value of $86,580.00. Following the completion of the transaction, the director now directly owns 7,911 shares of the company’s stock, valued at $342,467.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Richard J. Berman sold 2,708 shares of the stock in a transaction on Tuesday, August 16th. The stock was sold at an average price of $43.05, for a total value of $116,579.40. Following the sale, the director now owns 107,203 shares in the company, valued at $4,615,089.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Robert J. Hariri sold 2,000 shares of the stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $43.29, for a total value of $86,580.00. Following the completion of the sale, the director now owns 7,911 shares in the company, valued at approximately $342,467.19. The disclosure for this sale can be found here. 9.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cryoport

A number of institutional investors and hedge funds have recently made changes to their positions in CYRX. Harbor Investment Advisory LLC raised its position in Cryoport by 69.7% during the second quarter. Harbor Investment Advisory LLC now owns 886 shares of the consumer goods maker’s stock valued at $27,000 after purchasing an additional 364 shares in the last quarter. First Horizon Advisors Inc. raised its position in Cryoport by 132.3% during the first quarter. First Horizon Advisors Inc. now owns 1,080 shares of the consumer goods maker’s stock valued at $38,000 after purchasing an additional 615 shares in the last quarter. Nisa Investment Advisors LLC raised its position in Cryoport by 357.1% during the second quarter. Nisa Investment Advisors LLC now owns 1,280 shares of the consumer goods maker’s stock valued at $40,000 after purchasing an additional 1,000 shares in the last quarter. Pinebridge Investments L.P. purchased a new stake in Cryoport during the fourth quarter valued at about $77,000. Finally, Captrust Financial Advisors raised its position in Cryoport by 308.3% during the second quarter. Captrust Financial Advisors now owns 2,319 shares of the consumer goods maker’s stock valued at $72,000 after purchasing an additional 1,751 shares in the last quarter. Hedge funds and other institutional investors own 90.33% of the company’s stock.

Cryoport Stock Down 7.2 %

Shares of Cryoport stock opened at $29.51 on Friday. Cryoport has a one year low of $19.82 and a one year high of $86.30. The company has a debt-to-equity ratio of 0.73, a current ratio of 14.21 and a quick ratio of 13.69. The stock’s 50-day moving average is $36.07 and its 200 day moving average is $31.09. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -4.78 and a beta of 1.17.

Cryoport (NASDAQ:CYRXGet Rating) last announced its earnings results on Thursday, August 4th. The consumer goods maker reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.08). Cryoport had a negative net margin of 125.96% and a negative return on equity of 14.43%. The business had revenue of $64.20 million for the quarter, compared to the consensus estimate of $64.58 million. During the same quarter in the previous year, the company earned ($0.16) EPS. The firm’s revenue for the quarter was up 14.2% on a year-over-year basis. Equities research analysts anticipate that Cryoport will post -0.78 EPS for the current year.

About Cryoport

(Get Rating)

Cryoport, Inc, a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle.

See Also

Analyst Recommendations for Cryoport (NASDAQ:CYRX)

Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.